Health · Medical Research · 17 hrs ago
Samsung Bioepis presents phase 3 results for Keytruda biosimilar candidate
Samsung Bioepis presented phase 3 study results for a candidate biosimilar to Keytruda, an immune-based cancer treatment.
The company shared the findings at a recent immunotherapy conference in Arizona in the United States.
A biosimilar is a medicine designed to be highly similar to an existing biological medicine.
Keytruda was launched by Merck in 2014 and works by helping immune cells attack cancer cells.
It recorded sales of $31.7 billion last year, according to the story.
The announcement did not give details of the trial findings or say what the next step will be.
Samsung Bioepis presented phase 3 study results for its Keytruda biosimilar candidate.
The results were presented at the Society for Immunotherapy of Cancer meeting in Arizona, United States.
The company announced the presentation on November 9.
Keytruda is an immunotherapy cancer drug launched by Merck in 2014.
Keytruda recorded sales of $31.7 billion last year.
- Who
- Samsung Bioepis.
- What
- It presented phase 3 study results for its Keytruda biosimilar candidate.
- When
- The results were presented recently; the announcement was made on November 9.
- Where
- At a Society for Immunotherapy of Cancer meeting in Arizona, United States.
- Why
- Not stated.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Company
- Samsung Bioepis
- Drug candidate
- Keytruda biosimilar
- Study stage
- Phase 3
- Presentation location
- Arizona, United States
- Announcement date
- November 9